September 28, 2010
Ozurdex approved for non-infectious uveitis
After a single injection of Ozurdex the percent of patients reaching a vitreous haze score of zero (where a score of zero represents no inflammation) was statistically significantly greater for patients in the Ozurdex treated group versus sham (47% versus 12%, respectively) at the week eight primary endpoint. In addition, the percent of patients achieving a 3-line improvement in BCVA was 43% in the Ozurdex treated group, versus 7% for the sham group at week eight.
Ozurdex is a biodegradable implant that delivers an extended release of the corticosteroid dexamethasone via intravitreal injection with Allergan's proprietary Novadur solid polymer delivery system.
For more information call (800) 433-8871 or visit www.allergan.com.